Magnetic sphincter augmentation with the LINX device for gastroesophageal reflux disease after U.S. Food and Drug Administration approval

American Surgeon

Volumn 80, Issue 10, 2014, Pages 1034-1038

  Reynolds, Jessica L ^a   Zehetner, Joerg ^a   Bildzukewicz, Nikolai ^a   Katkhouda, Namir ^a   Dandekar, Giovanni ^a   Lipham, John C ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; INFUSION FLUID;

ADULT; AGED; ANTI REFLUX IMPLANT; ARTICLE; CLINICAL EFFECTIVENESS; DEHYDRATION; DEVICE APPROVAL; DYSPHAGIA; ESOPHAGUS MOTILITY; ESOPHAGUS SPASM; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROESOPHAGEAL REFLUX; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OPERATION DURATION; POSTOPERATIVE COMPLICATION; POSTOPERATIVE NAUSEA AND VOMITING; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PROSPECTIVE STUDY; QUALITY OF LIFE; STOMACH FUNDOPLICATION; TREATMENT RESPONSE; URINE RETENTION; FOLLOW UP; LAPAROSCOPY; LOWER ESOPHAGUS SPHINCTER; MAGNET; MIDDLE AGED; PROCEDURES; PROSTHESES AND ORTHOSES; PROSTHESIS IMPLANTATION; SURGERY; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ESOPHAGEAL SPHINCTER, LOWER; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; LAPAROSCOPY; MAGNETS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTHESES AND IMPLANTS; PROSTHESIS IMPLANTATION; QUALITY OF LIFE; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84921749352     PISSN: 00031348     EISSN: 15559823     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Dent J, El-Serag HB, Wallander MA, et al. Epidemiology of gastro-oesophageal reflux disease: a systematic review. Gut 2005;54:710-7.
2. Dean BB, Gano AD Jr, Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004;2:656-64.
3. Inadomi JM, McIntyre L, Bernard L, et al. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003;98:1940-4.
4. Papasavas PK, Keenan RJ, Yeaney WW, et al. Effectiveness of laparoscopic fundoplication in relieving the symptoms of gastroesophageal reflux disease (GERD) and eliminating antireflux medical therapy. Surg Endosc 2003;17:1200-5.
5. Hu Y, Ezekian B, Wells KM, et al. Long-term satisfaction and medication dependence after antireflux surgery. Ann Thorac Surg 2013;96:1246-51.
6. Richter JE. Gastroesophageal reflux disease treatment: side effects and complications of fundoplication. Clin Gastroenterol Hepatol 2013;11:465-71; quiz e439.
7. Kahrilas PJ. Clinical practice. Gastroesophageal reflux disease. N Engl J Med 2008;359:1700-7.
8. Katz PO, Zavala S. Proton pump inhibitors in the management of GERD. J Gastrointest Surg 2010;14(suppl 1):S62-6.
9. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97:575-83.
10. Lipham JC, DeMeester TR, Ganz RA, et al. The LINX Reflux Management System: confirmed safety and efficacy now at 4 years. Surg Endosc 2012;26:2944-9.
11. Bonavina L, DeMeester T, Fockens P, et al. Laparoscopic sphincter augmentation device eliminates reflux symptoms and normalizes esophageal acid exposure: one- and 2-year results of a feasibility trial. Ann Surg 2010;252:857-62.
12. Ganz RA, Peters JH, Horgan S, et al. Esophageal sphincter device for gastroesophageal reflux disease. N Engl J Med 2013;368:719-27.
13. Bonavina L, Saino G, Bona D, et al. One hundred consecutive patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease: 6 years of clinical experience from a single center. J Am Coll Surg 2013;217:577-85.